NCT03836690 (ToTem) is a Phase 1 clinical trial of CD62L- Tem in Lymphoma, sponsored by University College, London.

Who is sponsoring NCT03836690?

NCT03836690 is sponsored by University College, London.

What drugs are being tested in NCT03836690?

Interventions in NCT03836690: CD62L- Tem.

What condition does NCT03836690 study?

NCT03836690 studies Lymphoma, Leukemia, Myeloma, Myelodysplastic Syndromes, Severe Aplastic Anemia, Primary Immune Deficiency, Graft Vs Host Disease.

Is NCT03836690 still recruiting?

NCT03836690 is currently status unknown. Last updated 25 October 2019.

Last reviewed 2019-10-25 · How we verify

NCT03836690: ToTem

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation

Status unknown Phase 1 Last updated 25 October 2019

What this trial tests

Phase 1 trial testing CD62L- Tem in Lymphoma in 18 participants. Status unknown.

Timeline

21 October 2019

Primary endpoint
1 July 2022

1 April 2023

Quick facts

Lead sponsor	University College, London
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	21 October 2019
Primary completion	1 July 2022
Estimated completion	1 April 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

CD62L- Tem — full drug profile →

Conditions studied

Lymphoma — all drugs for Lymphoma →
Leukemia — all drugs for Leukemia →
Myeloma — all drugs for Myeloma →
Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →

Sponsor

University College, London

Who can join

Adults 16 to 70, any sex, with Lymphoma or Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Following stem cell transplantation, a major risk is graft-versus-host disease (GVHD). This occurs when donor immune cells that have been infused recognise the host's cells as 'foreign' and attack these cells. Prevention of GVHD relies upon depletion of donor immune T cells or drugs that block T cell function. However, these methods also increase the risk of life threatening infection. There is an important unmet need for better means of accelerating immune recovery following stem cell transplantation while avoiding GVHD. Pre-clinical studies have shown that infusion of donor CD62L- effector memory T cells (Tem) into the host improve immune recovery after allo-Stem Cell Transplant but do not cause GVHD. PURPOSE: This phase I dose escalation trial aims to determine the feasibility and safety of transfer of donor Tem following allogeneic stem cell transplantation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Prevention and Treatment of Acute Graft-versus-Host Disease in Children, Adolescents, and Young Adults.
Gatza E, Reddy P, Choi SW. · · 2020 · cited 41× · PMID 31931115 · DOI 10.1016/j.bbmt.2020.01.004
Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation.
Shafat MS, Mehra V, Peggs KS, Roddie C. · · 2020 · cited 22× · PMID 32849591 · DOI 10.3389/fimmu.2020.01694

Verify or expand the search:

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other University College, London trials

Trials by the same sponsor.

NCT07386652 — Intensive Comprehensive Aphasia Programme for People With Post-Stroke Aphasia · NA · not yet recruiting
NCT06924086 — The Children's Adaptive Deep Brain Stimulation for Epilepsy Trial · NA · recruiting
NCT07386678 — Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment · not yet recruiting
NCT07414940 — ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium · Phase 1, PHASE2 · not yet recruiting
NCT07214454 — TCDS for the Treatment of Chronic Migraine · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03836690 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University College, London
Last refreshed: 25 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03836690.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing